| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2028 | ‡‡‡‡‡ |
|
| 2027 | ‡‡‡‡‡ |
|
| 2026 | 1.56 |
—
—
—
|
| 2025 | 1.34 |
—
—
—
—
|
| 2024 | 1.16 |
—
—
—
—
|
| 2023 | 1.12 |
—
—
—
—
|
| 2022 | 1.10 |
—
—
—
—
|
| 2021 | 1.06 |
—
—
—
—
|
| 2020 | 1.00 |
—
—
—
—
|
| 2019 | 0.90 |
—
—
—
—
|
| 2018 | 0.82 |
—
—
—
—
|
| 2017 | 0.74 |
—
—
—
—
|
| 2016 | 0.68 |
—
—
—
—
|
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Cash | 294.45 | 213.82 | 198.04 | 49.27 |
| Receivables | 0.40 | 1.17 | 10.37 | 17.97 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 294.84 | 215.00 | 208.41 | 67.23 |
| 2023 | 2024 | 2025 | Q'26 | |
|---|---|---|---|---|
| Payables | 33.99 | 56.32 | 120.44 | 118.67 |
| ST’ Debt | — | — | — | — |
| Other | — | — | — | — |
| 33.99 | 56.32 | 120.44 | 118.67 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 142.78 | 161.35 | — | — |
—
|
| ’25 | 96.62 | 112.47 | 132.44 | 134.86 |
476.39
|
| ’24 | 63.07 | 68.89 | 77.38 | 86.94 |
296.29
|
| ’23 | 50.61 | 51.55 | 55.88 | 59.73 |
217.77
|
| ’22 | 46.48 | 47.55 | 50.29 | 51.81 |
196.13
|
| ’21 | 45.75 | 48.26 | 48.61 | 49.74 |
192.35
|
| ’20 | 44.34 | 44.17 | 45.69 | 44.14 |
178.33
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 90.37 | 134.75 | — | — |
—
|
| ’25 | 71.38 | 100.78 | 100.91 | 120.96 |
394.03
|
| ’24 | 48.82 | 52.98 | 67.25 | 75.21 |
244.25
|
| ’23 | 35.12 | 31.87 | 45.11 | 42.67 |
154.77
|
| ’22 | 34.58 | 33.72 | 42.37 | 33.74 |
144.42
|
| ’21 | 33.95 | 36.61 | 47.81 | 38.51 |
156.87
|
| ’20 | 36.52 | 31.42 | 40.44 | 37.35 |
145.74
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 15.48 | (70.47) | — | — |
—
|
| ’25 | 28.94 | (640.23) | 51.51 | (539.43) |
(1,099.21)
|
| ’24 | (22.26) | (90.90) | 10.95 | (478.76) |
(580.97)
|
| ’23 | 19.16 | (131.31) | 225.49 | (207.13) |
(93.78)
|
| ’22 | 33.62 | 10.10 | 39.56 | 53.84 |
137.12
|
| ’21 | (105.52) | 24.81 | 191.15 | (152.30) |
(41.86)
|
| ’20 | 33.10 | 2.70 | 23.21 | 75.42 |
134.44
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | 0.36 | 0.38 | — | — |
—
|
| ’25 | 0.35 | 0.35 | 0.35 | 0.50 |
1.57
|
| ’24 | 0.22 | 0.07 | 0.21 | 0.29 |
0.81
|
| ’23 | 0.19 | 0.00 | 0.08 | 0.22 |
0.50
|
| ’22 | (0.45) | 0.21 | 0.01 | 0.15 |
(0.08)
|
| ’21 | 0.21 | 0.22 | 0.12 | 0.19 |
0.74
|
| ’20 | 0.20 | 0.20 | 0.23 | 0.22 |
0.85
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 15.90 | 17.86 | 20.10 | 24.79 | — | — | — |
Low Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 23.59 | 23.49 | 33.15 | 38.32 | — | — | — |
High Price
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | 15 | 17 | 21 | 43 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.08 | 12.81 | 14.11 | 11.08 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 196.13 | 217.77 | 296.29 | 476.39 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 97.79% | 97.17% | 97.35% | 98.16% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.51) | 53.72 | 124.40 | 325.29 | ‡‡‡‡‡ | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.83%) | 24.67% | 41.99% | 68.28% | ‡‡‡ | ‡‡‡ | ‡‡‡ |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.51) | 53.72 | 124.40 | 320.29 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 58.23 | 58.46 | 63.02 | 102.48 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.03 | 2.06 | 1.91 | 2.34 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | (0.08) | 0.50 | 0.81 | 1.57 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.49 | 1.46 | 1.58 | 1.93 | ‡‡‡ | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.08) | (2.35) | (5.33) | (7.33) | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.42 | (0.89) | (3.75) | (5.40) | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 8.78 | 13.39 | 18.81 | 19.84 | ‡‡‡‡‡ | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 96.70 | 105.96 | 154.80 | 203.64 | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.00 | 45.61 | 34.24 | 23.18 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.23 | 10.87 | 14.13 | 15.46 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.13 | 1.67 | 1.44 | 1.82 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.94 | 12.35 | 14.82 | 16.96 | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.51 | (28.69) | (7.56) | (7.35) | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 144.42 | 154.77 | 244.25 | 394.03 | ‡‡‡ | ‡‡‡ | ‡‡‡ |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (7.29) | (248.55) | (825.22) | (1,493.24) | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 137.12 | (93.78) | (580.97) | (1,099.21) | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (10.77) | 260.85 | 158.68 | 87.97 | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 719.50 | 595.60 | 396.93 | 894.22 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 706.32 | 301.15 | 183.11 | 696.18 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 849.37 | 1,418.72 | 2,911.14 | 4,040.81 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.49%) | 2.88% | 4.51% | 7.45% | ‡‡‡‡‡ | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.67% | 4.91% | 3.95% | 4.17% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.90%) | 4.70% | 5.76% | 9.20% | ‡‡‡‡‡ | — | — |
ROE
|
CareTrust REIT (CTRE) has delivered resilient growth in the healthcare real estate sector, with revenue surging from $105 million in 2016 to $296 million in 2024—a 36% year-over-year leap—fueled by acquisitions, rent escalations, and post-COVID recovery in skilled nursing and senior housing. Despite a 2022 net loss amid pandemic operator struggles, profitability rebounded sharply to $124 million in 2024, with gross margins holding steady at 97-98% and analysts forecasting explosive jumps: $439 million revenue and $289 million net income in 2025, scaling further through 2027. EPS is projected to climb from $0.81 to $1.62, underscoring CTRE’s pricing power amid America’s aging population.
The stock has mirrored these fundamentals, roughly doubling from pandemic lows to $23-33 highs by 2024, with reasonable valuations (PE compressing to 25-34, PS at 14.1) and a fortified balance sheet: debt slashed 33% to $397 million, net debt halved, and free cash flow turning solidly positive at $1.49 per share. Efficiency shines with $14.1 million revenue per employee (just 21 staff), while ROE nears 9% on demographic tailwinds and acquisition potential.
Yet risks like share dilution and operator defaults loom—will CTRE sustain this trajectory? Analysts see 2-10% upside, positioning it as a yield-plus-growth play in healthcare REITs. Dive into the full analysis for the numbers, charts, and forward signals.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.